Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TERAZOSIN | 10MG | TABLET | Resolved | 2018-01-17 | 2018-07-31 | 36350 |
| APO-TERAZOSIN | 5MG | TABLET | Resolved | 2018-01-17 | 2018-07-31 | 36353 |
| APO-TERAZOSIN | 1MG | TABLET | Resolved | 2018-01-31 | 2018-07-31 | 37743 |
| APO-TERAZOSIN | 2MG | TABLET | Resolved | 2018-02-01 | 2018-08-20 | 37986 |
| APO-TERAZOSIN | 1MG | TABLET | Resolved | 2023-06-16 | 2024-04-02 | 195250 |
| APO-TERAZOSIN | 2MG | TABLET | Resolved | 2023-06-16 | 2024-04-02 | 195253 |
| APO-TERAZOSIN | 5MG | TABLET | Resolved | 2023-06-16 | 2024-04-02 | 195256 |
| APO-TERAZOSIN | 10MG | TABLET | Resolved | 2023-06-16 | 2024-05-10 | 195259 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-05-26 | 2023-06-16 | 193212 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2024-04-12 | 2024-07-26 | 225005 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2024-05-03 | 2024-07-26 | 227065 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2019-02-13 | 2020-08-10 | 75632 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2018-11-16 | 2019-01-17 | 67034 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-07 | 2023-12-22 | 203843 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-15 | 2023-12-22 | 204417 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-12-01 | 2024-01-05 | 212377 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2017-11-01 | 2017-11-23 | 27773 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2018-01-31 | 2018-09-21 | 37746 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2018-02-01 | 2018-04-15 | 37989 |
| APO-TERBINAFINE | 250MG | TABLET | Resolved | 2017-05-24 | 2017-07-19 | 11053 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |